Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fielmann Group AGXSWX:FIE 80 Days Sales Outstanding is 7.09 as of Mar. 2026, which is 18% below its 10-year median of 8.66. GuruFocus rates XSWX:FIE with a GF Score™ of 80/100 and a GF Value™ of CHF50.48. The stock has 2 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Fielmann Group AG ranks better than 98.89% on this metric.
The historical rank and industry rank for Fielmann Group AG's Days Sales Outstanding or its related term are showing as below:
XSWX:FIE'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.75 Med: 8.66 Max: 9.89
Current: 8.02
During the past 13 years, Fielmann Group AG's highest Days Sales Outstanding was 9.89. The lowest was 6.75. And the median was 8.66.
XSWX:FIE's Days Sales Outstanding is ranked better than 98.89% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.455
vs XSWX:FIE: 8.02
Fielmann Group AG's Days Sales Outstanding
declined
from Mar. 2025 (7.68) to Mar. 2026 (7.09).
Fielmann Group AG (XSWX:FIE) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Fielmann Group AG Days Sales Outstanding Related Terms
Fielmann Group AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Fielmann Group AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FIE vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Fielmann Group AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fielmann Group AG Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fielmann Group AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Fielmann Group AG's Days Sales Outstanding falls into.
Fielmann Group AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fielmann Group AG (XSWX:FIE) has a Days Sales Outstanding of 7.09 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fielmann Group AG and its competitors. This is 18% below median its historical median of 8.66. Over the past decade, Fielmann Group AG's Days Sales Outstanding has ranged from 6.75 to 9.89. According to the industry distribution chart, Fielmann Group AG ranks #9 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Fielmann Group AG's Days Sales Outstanding too high?
Fielmann Group AG's current Days Sales Outstanding of 7.09 is 18% below median its 10-year median of 8.66. Over the past 10 years, this metric has ranged from a low of 6.75 to a high of 9.89. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.46. Fielmann Group AG's value of 7.09 is 89.2% below this industry median. Based on the distribution chart, Fielmann Group AG ranks #9 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fielmann Group AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Fielmann Group AG's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fielmann Group AG ranks #9 out of 810 companies for Days Sales Outstanding. This places Fielmann Group AG in the top 1% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.46. Fielmann Group AG's value of 7.09 is 89.2% below this benchmark. Historically, Fielmann Group AG's own Days Sales Outstanding has ranged from 6.75 to 9.89 over the past decade. While the company's 10-year median is 8.66 vs. the industry median of 65.46, Fielmann Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.46, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fielmann Group AG's current Days Sales Outstanding of 7.09 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fielmann Group AG and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fielmann Group AG's current Days Sales Outstanding is 7.09, which is 18% below median its own 10-year median of 8.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fielmann Group AG stock overvalued right now?
Fielmann Group AG (XSWX:FIE) has a current Days Sales Outstanding of 7.09. The stock's GF Value™ is CHF50.48, compared to a current price of CHF38.30 — trading 24.1% below its estimated fair value. The current Days Sales Outstanding is 7.09, which is 18% below median its 10-year median of 8.66 and 89.2% below the Medical Devices & Instruments industry median of 65.46. Fielmann Group AG's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Fielmann Group AG (XSWX:FIE), the current Days Sales Outstanding is 7.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fielmann Group AG (XSWX:FIE) Overvalued in 2026?
Based on GuruFocus' analysis, Fielmann Group AG stock appears to be undervalued.
The current stock price of CHF38.30 is trading 24.1% below its estimated GF Value™ of CHF50.48.
Key valuation signals for XSWX:FIE:
Days Sales Outstanding: 7.09 (18% below median its 10-year median of 8.66)
GF Value™: CHF50.48 vs. price of CHF38.30 (24.1% below fair value)
Industry Position: 89.2% below the Medical Devices & Instruments median (#9 of 810)
No single metric tells the full story. See the XSWX:FIE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fielmann Group AG is involved in the purchase and sale of goods, in physical stores as well as wholesale and online, particularly in the optometric and hearing acoustics sectors, and especially sales of all kinds of vision aids - particularly glasses, eyeewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems, as well as personal protective equipment. Fielmann is involved in all levels of the optical industry value-added chain: designing, manufacturing, product offering, and optician services. The group was divided into six segments: Germany, Switzerland, Austria, Spain, North America, and Other. The majority of its revenue is generated from Germany.
80GF Score
Get the complete analysis for XSWX:FIE
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FIE has been successfully added to your 
